Peripheral nervous system manifestations: Taste impairment, smell impairment, vision impairment, and nerve pain
Skeletal muscular injury manifestation | Defined as a skeletal muscle pain and elevated serum creatine kinase level >200 U/L
214 COVID-19 patients were analyzed
Mean age: 52.7 years | Males 40.7%
Non-severe infection: 58.9% | Severe infection: 41.1%
Neurological manifestation: 36.4% (78 patients)
Skeletal muscle injury: 10.7%
Manifestations of neurologic manifestations include
Patients with severe disease
Were older: 58.2 vs 48.9 years (P < .001)
Had more underlying disorders (e.g. hypertension): 47.7% vs 32.5% (P=0.03)
Showed fewer typical symptoms of COVID-19, such as
Fever: 45.5% vs 73% (P < .001)
Dry cough: 34.1% vs 61.1% (P < .001)
Patients with more severe infection were more likely to have neurologic manifestations
Acute cerebrovascular disease: 5.7% vs 0.8% in non-severe
Impaired consciousness: 14.8% vs 2.4% in non-severe
Skeletal muscle injury: 19.3% vs 4.8% in non-severe
Patients with COVID-19 can have neurological manifestations, such as acute cerebrovascular diseases and impaired consciousness
Neurological manifestations are more common with severe forms of COVID-19
The authors state
During the epidemic period of COVID-19, when seeing patients with neurologic manifestations, clinicians should suspect severe acute respiratory syndrome coronavirus 2 infection as a differential diagnosis to avoid delayed diagnosis or misdiagnosis and lose the chance to treat and prevent further transmission
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan